Article ID Journal Published Year Pages File Type
8283670 Maturitas 2018 4 Pages PDF
Abstract
Intravaginal DHEA appears to be a safe and effective treatment for menopausal vulvovaginal atrophy and dyspareunia in most women. Further studies are required before it can be recommended for women with a history of thrombosis, cardiovascular disease or hormone-sensitive neoplasms.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Preview
Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase
Authors
, , ,